^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Platinum alkylating agent
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Lung Cancer
    Title:

    EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy

    Published date:
    07/19/2021
    Excerpt:
    ... 27 patients identified with EGFR ex20ins NSCLC at our institution, 18 (67%) received platinum-based chemotherapy for metastatic disease and had scans evaluable for response....The median PFS with platinum-based chemotherapy was 7.1 months (95% CI, 6.3 -13.7), and the median overall survival was 3.2 years (95% CI, 1.92 - NR).
    DOI:
    10.1016/j.cllc.2021.07.001